A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Trial Profile

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Minocycline (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Foamix
  • Most Recent Events

    • 15 Nov 2017 According to a Foamix Pharmaceuticals media release, last subject visit has been completed, ahead of schedule, in the long-term safety extension study and the top-line results from this safety are expected in by the end of this year.
    • 01 May 2017 Results were published in a Foamix media release.
    • 01 May 2017 Status changed from active, no longer recruiting to completed, according to a Foamix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top